IGF-1 LR3 vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Tirzepatide
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Tirzepatide |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation. |
| Best For |
Key Differences
Unique to IGF-1 LR3:
Unique to Tirzepatide:
Detailed Analysis
Commonalities
Both IGF-1 LR3 and Tirzepatide are commonly used for Fat Loss.
Which Should You Choose?
Tirzepatide has stronger evidence for Fat Loss.
Ready to Learn More?
Looking for trusted sources?